SIGA Will Seek FDA Approval of Monkeypox Treatment When Data Is Available, CEO Says


The monkeypox outbreak has sent shares of the drugmaker SIGA Technologies up more than 200% this year, though the company's monkeypox antiviral remains hard to access in the U.S.In an interview on Fri...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.


Leave a comment